Abstract:Proteolysis-targeting chimeras (PROTACs) are essential bifunctional molecules that target proteins of interest (POIs) for degradation by cellular ubiquitination machinery. Despite significant progress made in understanding PROTACs' functions, their therapeutic potential remains largely untapped. As a result of the success of highly flexible, scalable, and low-cost mRNA therapies, as well as the advantages of the first generation of peptide PROTACs (p-PROTACs), we present for the first time an engineering mRNA PROTACs (m-PROTACs) strategy. This design combines von Hippel-Lindau (VHL) recruiting peptide encoding mRNA and POI-binding peptide encoding mRNA to form m-PROTAC and promote cellular POI degradation. We then performed proof-of-concept experiments using two m-PROTACs targeting two cancer-related proteins, estrogen receptor alpha and B-cell lymphoma-extra large protein. Our results demonstrated that m-PROTACs could successfully degrade the POIs in different cell lines and more effectively inhibit cell proliferation than the traditional p-PROTACs. Moreover, the in vivo experiment demonstrated that m-PROTAC led to significant tumor regression in the 4T1 mouse xenograft model. This finding highlights the enormous potential of m-PROTAC as a promising approach for targeted protein degradation therapy. We developed mRNA proteolysis-targeting chimeras (PROTACs), a novel type of PROTACs, which incorporate mRNAs encoding E3 ligase recruiting peptide ligand and protein of interest (POI)-binding peptide ligand to promote cellular POI degradation. For the first time, we demonstrated that the encoding peptide PROTACs could degrade POIs and inhibit cell proliferation more effectively than the traditional peptide PROTACs, indicating their tremendous potential for targeted protein degradation therapy. image

Destruction of DNA-binding proteins by programmable O’PROTAC: Oligonucleotide-based PROTAC

Destruction of DNA‐Binding Proteins by Programmable Oligonucleotide PROTAC (O'PROTAC): Effective Targeting of LEF1 and ERG

Destruction of DNA-Binding Proteins by Programmable Oligonucleotide PROTAC (O'PROTAC): Effective Targeting of LEF1 and ERG (Adv. Sci. 20/2021)

PROTACs: an Emerging Targeting Technique for Protein Degradation in Drug Discovery

TF-PROTACs Enable Targeted Degradation of Transcription Factors.

Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy

ZIF-90-loaded DNAzyme-responsive PROTAC for the Self-Powered Degradation of NF-κB

Stimuli-activatable PROTACs for precise protein degradation and cancer therapy

PROTACs: New method to degrade transcription regulating proteins

Targeting Undruggable Transcription Factors with PROTACs: Advances and Perspectives

Hydrogen Peroxide-Inducible PROTACs for Targeted Protein Degradation in Cancer Cells

mRNA PROTACs: engineering PROTACs for high-efficiency targeted protein degradation

DNA framework-engineered chimeras platform enables selectively targeted protein degradation

PROTACs technology for targeting non-oncoproteins: Advances and perspectives

bioPROTACs as versatile modulators of intracellular therapeutic targets including proliferating cell nuclear antigen (PCNA)

Mrna PROTACs: Engineering PROTACs for High‐efficiency Targeted Protein Degradation

Small Molecule PROTACs in Targeted Therapy: an Emerging Strategy to Induce Protein Degradation.

Enzyme-catalyzed Activation of Pro-PROTAC for Cell-selective Protein Degradation

Small molecule PROTACs in targeted therapy: An emerging strategy to induce protein degradation

PROTAC: An Effective Targeted Protein Degradation Strategy for Cancer Therapy

Precise Modulation of Protein Degradation by Smart PROTACs